You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Justin Petrone covers consumer genomics, ancestry testing, and the microarray and biochip sector of the genomics market for GenomeWeb.
Driving the shift is a belief that standard STR testing is not always a reliable tool for determining complex family relationships.
The companies are positioning the test, called SeptiCyte Rapid, for use in triaging COVID-19 patients who could be at greater risk for progressing to sepsis.
The service is the first of its kind in the UK and relies on the Illumina NovaSeq 6000 platform to deliver results.
The next iteration of Ancestry's Health experience seeks to provide customers with actionable information about certain commonly inherited health conditions.
The Oslo-based company plans to develop a test that can identify high-risk individuals based on an epigenetic signature.
The software tool, currently in development, is set to be introduced next year and could also find application in other indications such as cancer.
The findings underscore the value of carrying out large-scale human genetic analyses as part of drug target identification and validation efforts.
While new ways to carry out pool testing for SARS-CoV-2 abound, questions remain about sensitivity issues and the regulation of such tests.
The launch of the company's Prism system earlier this month should support the development of an accompanying menu of tests to serve diverse users.
Polygenic risk scores have the potential to impact cancer screening, autoimmune disease testing, and therapeutics development, but more diverse data is needed.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.